Announcement on the progress of entrusted financial management
Release time:
2020-08-05
证券简称:尖峰集团 证券代码:600668 编号:临2018-012
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于委托理财进展情况的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l 委托理财受托方:渤海银行股份有限公司金华分行
l 委托理财金额:5000万元人民币
l 委托理财投资类型:保本浮动收益型结构性存款
l 委托理财期限:2018年4月26—2018年5月29日
一、本次委托理财概述
(一)本次委托理财的基本情况
公司于2018年4月25日与渤海银行股份有限公司金华分行(以下简称“渤海银行金华分行”)签署《渤海银行结构性存款产品交易协议书》,公司出资5,000万元人民币购买渤海银行金华分行发售的单位结构性存款S18409号理财产品,产品期限33天,预期年化收益率4.10%。本产品为保本浮动收益型理财产品。公司本次投资委托理财产品的资金来源为公司自有资金,且本次委托理财不构成关联交易。
(二)公司内部需履行的审批程序。
2017年8月25日,公司召开的第九届董事会第15次会议审议通过了《关于授权公司董事长决定委托理财的议案》。授权公司董事长行使不超过人民币2亿元的委托理财的决策权,在该额度内资金可以滚动使用,但任一时点存续的委托理财余额合计不得超过2亿元,每笔委托理财的期限均不得超过12个月。详见本公司在2017年8月29日在上海证券交易所网站披露的《关于授权董事长决定委托理财的公告》(临2017-024)。
2018年4月20日,公司召开的第十届董事会第3次会议审议通过了《关于授权公司董事长决定委托理财的议案》。授权公司董事长行使不超过人民币3亿元的委托理财的决策权,在该额度内资金可以滚动使用,但任一时点存续的委托理财余额合计不得超过3亿元,每笔委托理财的期限均不得超过12个月。详见本公司在2018年4月24日在上海证券交易所网站披露的《关于授权董事长决定委托理财的公告》(临2018-007)。
公司本次购买渤海银行金华分行发售的单位结构性存款S18409号理财产品,在公司第十届董事会第3次会议授权董事长决策范围之内。
二、本次委托理财协议主体的基本情况
1、交易对方名称:渤海银行股份有限公司金华分行,公司类型:股份有限公司分公司(非上市),营业场所:浙江省金华市双龙南街1051号南侧一至六层,负责人:陈洪棣,经营范围:吸收公众存款;发放短期、中期和长期贷款;办理国内外结算;办理票据承兑与贴现;代理发行、代理兑付、销售政府债券;代理买卖外汇;从事银行卡业务;代理收付款项;经营总行在中国银行业监督管理委员会批准的业务范围内授权的其他业务。(依法经须经批准的项目,经相关部门批准后方可开展经营活动)
2、渤海银行股份有限公司金华分行与本公司之间在产权、业务、资产、债权债务、人员等方面均不存在关联关系。
三、 本次委托理财合同的主要内容
(一)基本说明
公司本次购买理财产品的资金来源为公司自有资金,委托理财期限为2018年4月26日至2018年5月29日。渤海银行金华分行结构性存款产品为保本浮动收益型理财产品,预期年化收益率为4.10%,无需提供履约担保。本产品收益的计算中已包含(计入)银行的运营管理成本(如账户监管、资金运作管理、交易手续费等),公司无需支付或承担本产品下的其他费用或收费。
(二)产品说明
1、投资方向以及范围
结构性存款是指以企业的存款作为本金,挂钩利率、汇率、股票指数、商品价格等金融市场指标的创新型存款产品。如果投资方向正确,将获得额外收益;如果方向失误,将损失购买期权的费用,对于本金不造成影响。
2、收益计算
(1)本结构性存款产品收益兑付日,由渤海银行金华分行根据预设条件支付结构性存款预期收益;
(2)预期收益率获得条件:本产品为结构性存款产品,其结构性衍生产品部分挂钩标的:3个月期美元计伦敦同业拆借利率(3-month USD Libor)在伦敦时间上午11点的价格。客户的预期收益率按以下两种情况分别确定:
① 如果挂钩标的的期末价格小于或等于9.5%,则客户预期收益率为:【4.1】%(年);客户预期收益为:结构性存款本金×【4.1】%×实际产品天数/365;
② 如果挂钩标的的期末价格大于9.5%,则客户预期收益率为:【0.35】%(年), 即当期人民币活期存款利率;客户预期收益为:结构性存款本金×当期人民币活期存款利率×实际产品天数/365。
3、提前终止权:
客户无权提出提前终止(全部或者部分)本产品。
如出现如下情况,银行有权但无义务提前终止本产品:
① 国家金融政策出现重大调整并影响到终止本产品的正常运作;
② 市场发生极端重大变动或突发性事件等情形;
③ 本产品所投资的金融工具提前终止。
一旦银行提前终止本产品,将于确定的终止日前2个工作日通知客户,并在提前终止日后3个工作日内向客户返还本金及收益,收益按实际期限计算。
4、提前赎回权:
除本《产品说明书》另有约定外,客户无权提前赎回(全部或部分)本产品。
5、本金及收益兑付:
本结构性存款产品实际到期后,由渤海银行金华分行一次性支付本金及收益。
6、产品特点
本产品为保本浮动收益型结构性存款产品,风险较低,适合对于利率、汇率、商品价格等走势有一定见解和看法的投资人,并且保障客户本金,一定程度上降低了风险。
(三)敏感性分析
公司本次以自有资金5000万元购买的渤海银行金华分行结构性存款S18409号理财产品期限较短,不会对公司生产经营状况造成影响。在该投资期限内减少公司现金流净额5000万元,到期后预期为公司产生收益18.53万元。
(四)风险控制分析
本理财产品为保本收益型产品,银行确保公司本金安全,符合公司维护全体股东和公司利益的原则。公司始终将委托理财产品风险防控工作放在首位,严格按照内控制度有关规定,投资委托理财产品均为期限短、安全性高、流动性好的低风险银行理财产品。公司对购买的理财产品严格把关,谨慎决策。
四、公司累计进行的委托理财情况。
(一)尚未到期的理财产品
|
序号 |
受托人 |
理财产品类型 |
金额 (万元) |
起始日 |
到期日 |
|
1 |
招商银行金华江北支行 |
招商银行结构性存款CHZ00473号 |
3,000.00 |
2018/4/3 |
2018/5/28 |
|
2 |
广发银行金华分行 |
薪加薪16号人民币结构性存款产品 |
4,000.00 |
2018/4/3 |
2018/5/28 |
|
3 |
渤海银行金华分行 |
渤海银行S18283号结构性存款理财产品 |
3,000.00 |
2018/4/4 |
2018/5/29 |
|
4 |
招商银行金华江北支行 |
招商银行结构性存款CHZ00483号 |
3,000.00 |
2018/4/18 |
2018/5/28 |
(二)到期已收回本息的理财产品
|
序号 |
受托人 |
理财产品类型 |
金额 (万元) |
起始日 |
到期日 |
截止公告日已收回本金金额(万元) |
截止公告日获得收益(万元) |
|
1 |
渤海银行金华分行 |
渤海银行S17480号结构性存款理财产品 |
4,000.00 |
2017/10/12 |
2017/11/14 |
4,000.00 |
14.36 |
|
2 |
民生银行金华分行 |
与利率挂钩的结构性存款产品 |
3,000.00 |
2018/1/5 |
2018/2/14 |
3,000.00 |
14.79 |
|
3 |
渤海银行金华分行 |
渤海银行S17686号结构性存款理财产品 |
3,000.00 |
2018/1/9 |
2018/2/12 |
3,000.00 |
12.27 |
(三)公司累计委托理财金额
截止本公告日,本次委托理财前,公司已进行的委托理财累计金额为2.3亿元,其中:到期已收回1亿元,尚未到期的1.3亿元。
公司无其他未披露的委托理财事项。
特此公告
浙江尖峰集团股份有限公司
董事会
二〇一八年四月二十七日
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11